Long-term safety of vedolizumab for inflammatory bowel disease

Edward V Loftus Jr, Brian G Feagan, Remo Panaccione, Jean-Frédéric Colombel, William J Sandborn, Bruce E Sands, Silvio Danese, Geert D'Haens, David T Rubin, Ira Shafran, Andrejus Parfionovas, Raquel Rogers, Richard A Lirio, Séverine Vermeire, Edward V Loftus Jr, Brian G Feagan, Remo Panaccione, Jean-Frédéric Colombel, William J Sandborn, Bruce E Sands, Silvio Danese, Geert D'Haens, David T Rubin, Ira Shafran, Andrejus Parfionovas, Raquel Rogers, Richard A Lirio, Séverine Vermeire

Abstract

Background: Vedolizumab, a gut-selective α4 β7 integrin antibody, is approved for moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

Aim: To report the final results from the vedolizumab GEMINI long-term safety (LTS) study.

Methods: The phase 3, open-label GEMINI LTS study (initiated May 2009) enrolled patients with UC or CD from four prior clinical trials and vedolizumab-naïve patients. Vedolizumab LTS was evaluated; efficacy and patient-reported outcomes were exploratory endpoints.

Results: Enrolled patients (UC, n = 894; CD, n = 1349) received vedolizumab 300 mg IV every 4 weeks; median cumulative exposure was 42.4 months (range: 0.03-112.2) for UC and 31.5 months (range: 0.03-100.3) for CD. Over 8 years, adverse events (AEs) occurred in 93% (UC) and 96% (CD) of patients, with UC (36%) and CD (35%) exacerbations most frequent. Serious AEs were reported for 31% (UC) and 41% (CD) of patients. Vedolizumab discontinuation due to AEs occurred in 15% (UC) and 17% (CD) of patients. There were no new trends for infections, malignancies, infusion-related reactions, or hepatic events, and no cases of progressive multifocal leukoencephalopathy. Of the ten deaths (UC, n = 4; CD, n = 6), two were considered drug-related by local investigators (West Nile virus infection-related encephalitis and hepatocellular carcinoma). Continuous vedolizumab maintained clinical response long-term, with 33% (UC) and 28% (CD) of patients in clinical remission at 400 treatment weeks.

Conclusions: The safety profile of vedolizumab remains favourable with no unexpected or new safety concerns. These results further establish the safety of vedolizumab and support its long-term use (NCT00790933/EudraCT 2008-002784-14).

© 2020 Takeda Pharmaceuticals USA. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
GEMINI LTS patient enrolment. Patients were eligible for enrolment in GEMINI LTS who had completed the Phase 2 long‐term safety study or one of the three Phase 3 GEMINI studies. In addition, a cohort of vedolizumab‐naïve patients were recruited directly into GEMINI LTS. CD, Crohn's disease; HBI, Harvey‐Bradshaw Index; IV, intravenous; LTS, long‐term safety; Q4W, every 4 weeks; UC, ulcerative colitis
Figure 2
Figure 2
Clinical response over time in patients with UC or CD. Clinical response was assessed at baseline, weeks 4, 8, 12 and every 8 weeks thereafter. For patients with UC, clinical response was defined as a decrease in the partial Mayo score of ≥2 points and ≥25% from baseline, with an accompanying decrease in rectal bleeding subscore of ≥1 point from baseline or absolute rectal bleeding subscore of ≤1 point. For patients with CD, clinical response was defined as a ≥3‐point decrease from baseline in the HBI score. Baseline was defined as the last assessment prior to the first dose of study drug administration in GEMINI 1 for patients with UC and GEMINI 2 for patients with CD. For patients who discontinued the study, the final assessed value of clinical response was carried forward to the end of the study. CD, Crohn's disease; HBI, Harvey‐Bradshaw Index; UC, ulcerative colitis
Figure 3
Figure 3
Clinical remission over time in patients with UC or CD. Clinical remission was assessed at baseline, Weeks 4, 8, 12 and every 8 weeks thereafter. For patients with UC, clinical remission was defined as a partial Mayo score of ≤2 with no individual subscore >1. For patients with CD, clinical remission was defined as an HBI score ≤4. For patients who discontinued the study, the final assessed value of clinical response was carried forward to the end of the study. CD, Crohn's disease; HBI, Harvey‐Bradshaw Index; UC, ulcerative colitis
Figure 4
Figure 4
Health‐related quality of life (HRQOL) by indication and assessment tool in patients with UC or CD. HRQOL was assessed at baseline and week 26 and then every 24 weeks for the first 4 years, and yearly from Year 5 onward. Assessments tools included A. IBDQ total score, B. SF‐36 total score, C. EQ‐5D total score, and D. EQ‐5D VAS

References

    1. Torres J, Mehandru S, Colombel J‐F, Peyrin‐Biroulet L. Crohn's disease. Lancet. 2017;389:1741‐1755.
    1. Ungaro R, Mehandru S, Allen PB, Peyrin‐Biroulet L, Colombel J‐F. Ulcerative colitis. Lancet. 2017;389:1756‐1770.
    1. ENTYVIO (vedolizumab) prescribing information. Takeda Pharma/S. Revised 04/01/2019.
    1. Vedolizumab [summary of product characteristics]. Taastrup, Denmark: Takeda Pharma A/S; Revised 04/01/2019.
    1. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699‐710.
    1. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711‐721.
    1. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618‐627.e3.
    1. Loftus EV Jr, Colombel JF, Feagan BG, et al. Long‐term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis. 2017;11:400‐411.
    1. Vermeire S, Loftus EV Jr, Colombel JF, et al. Long‐term efficacy of vedolizumab for Crohn's disease. J Crohns Colitis. 2017;11:412‐424.
    1. Colombel J‐F, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017;66:839‐851.
    1. König H‐H, Ulshöfer A, Gregor M, et al. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14:1205‐1215.
    1. McColl E, Han SW, Barton JR, Welfare MR. A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF‐36 in people with ulcerative colitis. Qual Life Res. 2004;13:805‐811.
    1. Pallis AG, Mouzas IA, Vlachonikolis IG. The inflammatory bowel disease questionnaire: a review of its national validation studies. Inflamm Bowel Dis. 2004;10:261‐269.
    1. McAuliffe ME, Lanes S, Leach T, et al. Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database. Curr Med Res Opin. 2015;31:1655‐1664.
    1. Colombel J‐F, Sandborn WJ, Reinisch W, et al. Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2018;47:219‐228.
    1. Sands BE, Peyrin‐Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate‐to‐severe ulcerative colitis. N Engl J Med. 2019;381:1215‐1226.
    1. Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015;64:77‐83.
    1. Card T, Xu J, Liang H, Bhayat F. What is the risk of progressive multifocal leukoencephalopathy in patients with ulcerative colitis or crohn's disease treated with vedolizumab? Inflamm Bowel Dis. 2018;24:953‐959.
    1. Magro F, Peyrin‐Biroulet L, Sokol H, et al. Extra‐intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis. 2014;8:31‐44.
    1. Gallagher MP, Kelly PJ, Jardine M, et al. Long‐term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol. 2010;21:852‐858.
    1. Mariette X, Matucci‐Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta‐analysis. Ann Rheum Dis. 2011;70:1895‐1904.
    1. Feagan BG, Sandborn WJ, Colombel J‐F, et al. Incidence of arthritis/arthralgia in inflammatory bowel disease with long‐term vedolizumab treatment: post hoc analyses of the GEMINI trials. J Crohns Colitis. 2019;13:50‐57.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다